Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain by Verma, Rati et al.
 
Verma et al., Supplementary Material 
Page 1 
Supporting Online Material for Science 1100946 
 
Ubistatins Inhibit Proteasome-Dependent Degradation  
by Binding the Ubiquitin Chain 
 
Rati Verma, Noel R. Peters, Mariapina D’Onofrio, Gregory P. Tochtrop,  
Kathleen M. Sakamoto, Ranjani Varadan, Mingsheng Zhang, Philip Coffino,  
David Fushman,  Raymond J. Deshaies, and Randall W. King 
 
Materials and Methods 
Preparation of Proteins for Screening 
 To construct a cyclin-luciferase fusion protein (pSP cyc-luc), the N-terminal 
sequence of Xenopus laevis cyclin B1, including amino acids 2-97, was amplified by 
PCR, digested with BstEII, and ligated into the pSP-lucNF expression vector (Promega). 
The resulting vector was sequence verified. The fusion protein was expressed by coupled 
in vitro transcription and translation in reticulocyte lysate using the SP6-TNT Coupled 
Reticulocyte Lysate System (Promega) and flash frozen in liquid nitrogen until the time 
of use. The parental pSP-lucNF vector was used to express unmodified luciferase. 
 A vector for expression of cyclin-luciferase in E. coli (pET cyc-luc) was also 
constructed; this protein behaved identically in all assays to the protein expressed in 
reticulocyte lysate, but could be made in higher quantities necessary for screening. pSP 
cyc-luc was digested with HindIII and XhoI. The resulting 1949 bp fragment containing 
the cyclin B1-luciferase sequence was ligated into the pET 28b expression vector 
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(Novagen) containing an N-terminal hexahistidine tag for protein purification. To express 
this fusion protein, one liter of LB containing E. Coli strain BL21(DE3) was grown at 37 
°C to an OD600 of 0.6. Expression was induced for 3 hrs with 1mM IPTG. The cells 
were pelleted and lysed, and protein purified by Ni-NTA batch purification under native 
protein conditions (Qiagen). Sea urchin cyclin B∆90 was prepared as described (S1). 
Methylated ubiquitin was prepared by reductive methylation of bovine ubiquitin as 
described (S2).  
 
Preparation of Xenopus Egg Extracts 
 Xenopus egg extracts were prepared from eggs laid overnight according to the 
protocol of Murray (S3) with the exception that eggs were activated with
2 µg/ml calcium ionophore (A23187, free acid form, Calbiochem) for forty minutes 
prior to the crushing spin. Extracts were frozen in liquid nitrogen and stored at -80 °C. 
Eggs laid from 40 frogs typically yielded a total 70 ml of cytoplasmic extract. 
 
Assay Validation 
 Extracts were rapidly thawed and diluted to a final concentration of 75% in 
extract buffer (XB) just prior to assay (XB; 100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 
10 mM Potassium HEPES, pH 7.7, 50 mM sucrose). Extracts were kept on ice and 
supplemented with 1 mg/ml bovine ubiquitin (Sigma) unless otherwise stated. Cyc-luc 
expressed in reticulocyte lysate was diluted 1/200 for most assays. High-throughput 
screening utilized the bacterially expressed and purified cyclin-luc fusion protein, which 
was added to extracts at a final concentration of 0.1 µg/ml. To induce entrance into 
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mitosis, cyclin B∆90 protein was added to a final concentration of 10 µg/ml. For the dose 
response analysis (Fig. S2), inhibitors were purchased from Calbiochem (San Diego, CA) 
and dissolved in DMSO as 10 mM stocks. Cyclin-luciferase and cyclin B∆90 were mixed 
with interphase extract and placed on ice. Inhibitors were then added to extracts to yield a 
final DMSO concentration of 1%. 10 µl aliquots of extract were distributed into 384-well 
white Cliniplates (Labsystems), and cell cycle progression was initiated by warming the 
samples to room temperature. After 60 minutes, 30 µl of luciferin reagent (20 mM 
Tricine pH 7.8, 470 µM D-Luciferin [Molecular Probes]), 270 µM Coenzyme A, 0.1 mM 
EDTA, 33 mM DTT, and 530 µM ATP) was added using a multidrop dispenser 
(Labsystems). Luminescence was measured on an Analyst plate reader (LJL Biosystems). 
The values for 3 replicates were averaged. For the dose response analysis (Fig S2), 
percent inhibition was calculated as 100*(T-M)/(I-M) where T equals the test value for 
the inhibitor, M equals the value in a mitotic extract lacking inhibitor, and I equals the 
value in an interphase extract. For the experiment in Fig. S1, methylated ubiquitin was 
added to interphase extracts at a concentration of 1 mg/ml in the presence or absence of 
added unmodified ubiquitin (1 mg/ml) used as competitor. Cyclin-luciferase and cyclin B 
delta 90 were then added. After 60 minutes, the reactions were stopped and analyzed as 
described above. 
 
Chemical Libraries and Chemical Characterization of Active Compounds 
 Compound collections screened included 16,320 compounds from Chembridge 
Corporation (San Diego, CA; Diverset E); 1991 compounds from the NCI Diversity set, 
and 90,802 compounds from the NCI open collection. Compounds that retained activity 
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after retesting were reobtained as dry powders and characterized by LC-MS; only 
compounds that were greater than 90% pure with an appropriate mass were evaluated in 
further experiments and presented in Figure 1.  
 For ubistatin A (C92), we performed additional structural characterization of a 
sample of dry powder provided by the NCI (NSC665534). NMR spectra were recorded at 
ambient temperature in D2O with a 5 mm probe operating at 500 MHz (1H) or 75 MHz 
(13C).  For 1H NMR the internal reference was TSP (δ 0.00).  1H NMR (D2O) δ 8.51 (d, 
J=3.0 Hz, 2H), 8.21 (d, J=2.1 Hz, 2H), 7.98(br, J=8.1 Hz, 2H), 7.80 (m, 6H), 7.60 (dd, 
J=8.4; 2.1 Hz, 2H) 7.35 (dd, J=8.4; 4.2 Hz, 2H), 6.82 (d, J=8.7 Hz, 2H, H-d). These 
measurements are identical to those reported in the literature (S4). Elemental analysis was 
also performed (M-H-W laboratories, Phoenix AZ): Anal. Calcd. for 
C34H20N4Na4O16S4;C, 42.50; H, 2.10; N, 5.83.  Found: C, 42.65; H, 2.24; N, 5.88. 
 
High-throughput screening 
 Chilled interphase Xenopus extracts containing cyclin B ∆90 and cyclin-luciferase 
were spread onto chilled custom-designed 1536-well plates (S5) that held 2 microliters of 
extract per well. 100 nl of compound (5-10 mM in DMSO) was then transferred into the 
assay plate using a custom-designed pin-transfer robot (S5). After a 60 minute incubation 
at room temperature, a PixSys 3200 dispenser (Cartesian Technologies, Irvine, CA) was 
used to dispense 200 nl of a 10x concentrated luciferin solution to each well of the assay 
plate. Immediately after filling, the plate was imaged using the Leadseeker system 
(Amersham Pharmacia Biotech, Amersham, U.K.). Exposure times were typically 2 
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minutes. Image analysis and quantitation was performed using the MCID Assayvision 
software (Imaging Research Incorporated, St. Catherines, Canada).  
 A total of 109,113 compounds were screened in duplicate. A low threshold was 
set for identification of initial hits, and included compounds that increased the 
luminescence reading by two-fold above the median value calculated for all wells on the 
plate. We included compounds that scored on either of the duplicate set of plates, and 
noted that about 65% of the compounds scored on both plates, whereas 35% were active 
only on a single plate. This rate of overlap may be a result of variability in the amount of 
compound transferred. The initial screen identified a total of  1017 hits (247 from the 
Chembridge Library and the NCI diversity set; 770 from the NCI open collection). In the 
next step, we cherry picked the DMSO stocks of active compounds to create a new 
master plate. All of the hits from the Chembridge Library and the NCI diversity set were 
replated, whereas only 444 compounds from the NCI open collection were replated, as 
high fraction of compounds were excluded due to chemical or structural considerations 
(compounds with very simple structures, reactive structures, or which contained metal 
complexes were excluded). The resulting 691 compounds were then retested in 384-well 
plates at 200 µM concentration under the conditions described for validation of the assay. 
In this case, compounds were prediluted in XB prior to addition to extracts by pipetting, 
assuring more accurate compound concentration. A large number of compounds failed to 
retest as positive at this point, presumably due to the higher concentrations used in the 
primary screen. The 96 most active compounds were then reobtained as dry powders 
from either Chembridge or the NCI. These compounds were retested in the four assays 
described in Table 1, at 200 µM concentration, with the exception of C10 and C92, which 
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were tested at 100 µM concentration. Compounds were tested at high concentration, as 
Xenopus extract generally require much higher concentration of compounds than 
corresponding experiments in mammalian cells or with purified proteins, due to the high 
concentration of lipid and protein in extracts. The data in Table 1 represent the 22 most 
active compounds (compounds that showed at least 30% inhibition) whose structures 
could also be confirmed by LC-MS analysis. Table S1 provides the relevant Chembridge 
ID or NCI identification numbers for each of these compounds. Structures of these 
compounds will also be accessible on the Chembank web site upon publication 
(http://chembank.med.harvard.edu/).  
 
Retesting of Active Compounds 
 Dry compounds were redissolved at 20 mM concentration in DMSO, or at 10 mM 
in a 50:50 water:DMSO mixture (for C10 and C92). These compounds were then diluted 
ten-fold in XB and mixed thoroughly. To retest compounds under conditions of the 
original screen, in which compounds were added prior to mitotic entry, chilled interphase 
extract was mixed with cyclin B ∆90 (10 µg/ml) and cyc-luc (0.1 µg/ml) in bulk and then 
27 µl of extract was pipetted to each well of a chilled 384-well plate. Three microliters of 
each compound (diluted in XB) was then added to each well, and then compounds mixed 
thoroughly, yielding a final concentration of 200 µM (100 µM for C10 and C92). Plates 
were warmed to room temperature. After 70 minutes, 5 µl aliquots were transferred to 
another plate, and then 30 µl of luciferin reagent was added to each well and 
luminescence measured. Percent inhibition was calculated as described above. The 
reported values represent the average of three independent measurements. To determine 
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whether compounds lost inhibitory activity when added after mitotic entry, interphase 
extracts were treated with 10 µg/cyclin B ∆90 for 50 minutes at room temperature to 
drive entry into mitosis and then chilled on ice. Cyc-luc was then added, and then 27 µl 
of extract was pipetted to each well of a chilled 384-well plate. Three microliters of each 
compound (diluted in XB) was then added to each well, and then compounds mixed 
thoroughly. Plates were warmed to room temperature. After 60 minutes, 5 µl aliquots 
were transferred to another plate, and then 30 µl of luciferin reagent was added to each 
well and luminescence measured. To determine whether compounds inhibited Cdh1-
induced proteolysis, recombinant Cdh1 (0.1 µg/ml) and cyc-luc were added to chilled 
interphase extracts. Extracts were then pipetted and compounds added as above. Plates 
were warmed to room temperature and incubated for three hours, following which 
luminescence was measured as above. To determine whether compounds inhibited 
degradation of a β-catenin reporter protein, chilled interphase extracts received 
recombinant Axin and beta-catenin-luciferase reporter as described (S6). Extracts were 
aliquoted to chilled plates and compounds distributed as described above. Plates were 
warmed to room temperature, incubated for three hours, and luminescence measured. In 
all assays, percent inhibition was calculated as 100*(T-A)/(I-A) where T equals the test 
value for the inhibitor, I equals the value for inactive interphase extracts lacking either 
cyclin B ∆90, Cdh1, or Axin protein, and A equals the value for an extract that lacks a 
chemical inhibitor but is stimulated to degrade the reporter protein by addition of cyclin 
B ∆90, Cdh1, or Axin protein. In the case of Cdh1 addition, we noted that many of the 
Class I compounds led to stimulation of proteolysis under these conditions (Table 1). As 
the same effect was observed with addition of the kinase inhibitor roscovitine to extracts, 
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we believe that these compounds stimulate Cdh1-dependent degradation by inhibiting an 
unidentified kinase in interphase Xenopus extracts.  
 
Preparation of UbSic1 
 Sic1, expressed in E. coli as a Maltose-binding-protein chimera tagged at the C-
terminus with the MycHis6 tag (MbpSic1mycHis6) was purified as described (S7). It was 
phosphorylated and ubiquitinated utilizing insect expressed kinase and SCFCdc4 
complexes as described (S8). Ubiquitinated MbpSic1mycHis6 was designated UbSic1 in the 
text. 
 
Purification of 26S proteasomes 
 26S proteasomes were purified from S. cerevisiae cells expressing a Flag-tagged 
proteasomal subunit (PRE1) essentially as described (S9). Briefly, lysates were 
immunoaffinity purified on anti-Flag resin in the presence of 2mM ATP and 5 mM 
MgCl2, and eluted with Flag peptide. 26S proteasomes were purified from rat liver as 
described (S10). 
 
Degradation of UbSic1 
 Ubiquitinated Sic1 (~300 nM) was incubated with purified 26S proteasomes 
(~100 nM) at 30°C for 5 min (S9).  The reaction tubes were transferred to ice and 
quenched with 5X Laemmli SDS sample buffer. Aliquots were resolved by SDS-PAGE, 
transferred to nitrocellulose, and immunoblotted with polyclonal anti-Sic1 antibody. 
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Deubiquitination of UbSic1 
 Purified 26S proteasomes were preincubated with 100 uM epoxomicin at 30°C for 
45 min before addition of UbSic1 (S11). Reactions were processed as above. 
 
Purification of Gst-Fusion Proteins 
 Recombinant proteins were purified as described (S12). 
 
Binding of UbSic1 to 26S proteasomes 
 26S proteasomes were immunoprecipitated with anti-Flag resin from tagged and 
untagged control strains and incubated with 1 mM phenanthroline, 2.5 µM Ub-aldehyde, 
and 100 µM MG132 at 4°C for 45 min. UbSic1 was then added in binding buffer 
containing 25 mM Tris, pH 7.5, 1 mM ATP, 100 mM NaCl, 5 mM MgCl2, 0.2 % Triton 
in the presence or absence of 5 µM C92. Following binding, beads were washed twice 
with the same buffer, and once with 25mM Tris, 5mM MgCl2, 1 mM ATP. Washed 
beads were resuspended in 2X SDS sample buffer and aliquots analyzed by 
immunoblotting with anti-Sic1 antibody. 
 
Binding of UbSic1 to Gst-Fusion proteins 
 Recombinant Gst-Rpn10 and Gst-Rad23 were immobilized on glutathione 
sepharose beads. UbSic1 was added in binding buffer containing 25 mM Tris, pH 7.5, 
150 mM NaCl and 0.2 % Triton in the presence or absence of C92 or C59.  Following 
binding at 4°C for 90 minutes, the beads were centrifuged, and washed twice with the 
same buffer, and twice with buffer containing 25mM Tris, pH 7.5. They were then 
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resuspended in an equal volume of 2X SDS sample buffer. Aliquots were analyzed by 
immunoblotting. 
 
Microinjection experiments 
 HEK-293 cells stably transfected with a plasmid that expresses AR-GFP were 
microinjected with 0.2 pl (5-10% of cell volume) of a 200 mM KCl solution containing 
10 µM Protac and 50 mg/ml rhodamine dextran (MW 10,000 Da). For C92 and 
proteasome inhibition experiments, cells were co-injected with 1 µM C92 or epoxomicin 
(yielding a final intracellular concentration of 50-100 nM) and Protac (10µM) as 
previously described (S13).  
 
Ornithine Decarboxylase Degradation Experiments 
 Assays of the degradation of 35S -mODC were performed as described (S10) in a 
volume of 20 µl at 37 °C and contained: 50mM Tris-HCl pH7.5, 5 mM MgCl2, 1 mM 
ATP, 10 mM KCl, 10 % glycerol, an ATP regenerating buffer (2 mM DTT, 10 mM 
creatine phosphate, 1.6 mg/ml creatine kinase), 2 mg/ml BSA, 50 nM 35S-mODC, and 50 
nM rat proteasomes. Reactions were preincubated with inhibitors or cold ODC for 10 
minutes, and degradation initiated by addition of proteasomes. Reactions were quenched 
after 30 minutes by adding 140 µl of 20 % trichloroacetic acid. After microcentrifugation 
for 30 min at 14000g, 150 µl of the supernatant was removed for scintillation counting  
to determine released counts. Total counts were obtained using water in place of 
trichloroacetic acid. Background of released counts without proteasome was about 0.5% 
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of total counts. Percentage of degradation of labeled ODC was determined by the 
formula: percent degradation= (released cam-background cpm)/total cpm.   
 
NMR studies 
 Synthesis of segmentally 15N-labeled Ub2 chains was performed as described in 
(S14). Ubiquitin monomers and C170S-E225K were expressed and purified as described in 
(S15). 15N-labeled Ub (D77) and Ub (K48C) were expressed in E. coli cells grown in 
minimal media with 15NH4Cl as the sole source of nitrogen. E1 and Ub C-terminal 
hydrolase were from Boston Biochem Inc., and ethyleneimine was from Chemservice.   
 All NMR measurements were performed at 24 oC on a Bruker DRX spectrometer 
operating at 1H resonance frequency of 600.13 MHz. The protein samples (concentration 
range from 0.1-0.6 mM) were prepared in 20 mM phosphate buffer, pH 6.8, containing 
7% D2O and 0.02% NaN3. 1H-15N HSQC spectra were acquired with spectral widths of 
7.2 kHz and 2 kHz in the 1H and 15N dimensions, respectively. For each 2D plane, 128 t1 
increments were collected, each consisting of 1024 complex points.  
 For NMR titration studies ubistatin A was added to the di-ubiquitin sample in 
small steps from a 1 mM stock solution in the same buffer as the protein. The titration 
continued up to a molar ratio, ubistatin:Ub2, of 4:1 (distal-domain-labeled Ub2), 5:1 
(proximal-domain-labeled Ub2). Binding of ubistatin A was monitored by signal 
attenuation and shifts in the resonance peak positions of the backbone amides in each Ub 
domain. Site-specific perturbations saturated at a molar ratio of ubistatin A:Ub2 of 3:1. 
The combined amide chemical shift perturbations were computed as ∆δ = [(∆δH)2 + 
(∆δN/5)2]½, where ∆δH and ∆δN are the chemical shift differences (for 1H and 15N, 
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respectively) between the free and ubistatin A-bound di-ubiquitin for a given amide 
group. The signal attenuation for each residue was calculated as (1-I/Io)*100%, where Io 
and I are peak intensities in HSQC spectra of the free and C92-bound protein; the latter 
values were uniformly scaled to account for higher molecular weight of the complex and 
for the differences in the protein concentration and the experimental settings between the 
experiments. The atom coordinates used for Fig. 3 are from the crystal structure 
1AAR.pdb (S16).
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Figure Legends 
Fig. S1. Mitosis-specific degradation of a cyclin-luciferase fusion protein. Luciferase or 
cyclin-luciferase was added to an interphase extract. Recombinant cyclin B ∆90 was 
added to one sample to induce entrance into mitosis. After 60 minutes, luciferin was 
added and luminescence measured. (B) Cyclin-luciferase is stabilized by methylated 
ubiquitin. The experiment in part (A) was repeated as described above, except that 
methylated ubiquitin was added to a concentration of 1 mg/ml. Extracts were 
supplemented with no additional ubiquitin ("no ubiquitin") or 1 mg/ml ubiquitin ("plus 
ubiquitin"), to compete with methylated ubiquitin. (C) An image of a sample assay plate 
from the screen. The arrow indicates a well that was considered a “hit” in the screen.  
 
Fig. S2. Determination of sensitivity of the assay to a panel of inhibitors. Interphase 
extracts containing cyclin-luciferase were treated with compound and then induced to 
enter mitosis with cyclin ∆90 protein. Inhibitors were dissolved in DMSO and diluted to 
1% final volume in extract. After 60 minutes, luciferin was added and luminescence 
measured. Percent inhibition was calculated as 100*(T-M)/(I-M) where T equals the test 
value for the inhibitor, M equals the value in a mitotic extract lacking inhibitor, and I 
equals the value in an interphase extract. In testing known inhibitors, we noted that even 
potent inhibitors, such as roscovitine, required much higher concentrations in Xenopus 
extracts than in purified enzyme systems. For example, roscovitine exhibited an IC50 of 
30 µM in Xenopus extracts, whereas its reported IC50 against purified cyclin B1/cdc2 is 
650 nM (S17). We believe this is due to the high concentration of lipid and protein (>30 
mg/ml) in Xenopus extracts which may sequester compound. We also noted that MG132 
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and epoxomicin did not fully prevent loss of cyc-luc activity, even at high concentration 
(F). Assessment of proteins by western blotting, however, indicated that proteins are fully 
stabilized by higher concentrations of these inhibitors. We believe this discrepancy is due 
to proteasome-dependent unfolding and inactivation of the luciferase enzyme in the 
presence of  20S inhibitors.  
 
Fig. S3. Structures of Class I inhibitors.  
 
Fig. S4. Structures of Class II inhibitors.  
 
Fig. S5. (A) Complete inhibition of deubiquitination by 100 µM C59, and marginal 
inhibition by 100 µM C23.  Assays were performed and evaluated as summarized in the 
legend to Fig. 1B.  The metal chelating reagent phenanthroline is designated as “P”, and 
“Py” refers to the pyridine solvent that is used as the solvent for C23. (B) Titration curve 
for C59. (C) Inhibition of binding of ubiquitin conjugates to Gst-Rpn10 by C92 and C59, 
but not other compounds. The experiment was performed as described for Fig. 2B. 
 
Fig. S6. Class IIB compounds do not compromise 26S proteasome integrity at 
concentrations that inhibit ubiquitin-dependent proteolysis. (A) Purified 26S proteasomes 
were preincubated with test compounds before being resolved on a native gel. Following 
electrophoresis, the gel was stained with Coomassie Blue. (B) C92 does not affect 20S 
core activity. Same as (A), except that following electrophoresis, the gel was incubated 
with fluorescent substrate to determine peptidase activity, which was visualized using a 
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UV transilluminator (S9). C23 was also without effect (not shown), whereas C59 was too 
fluorescent by itself for this assay. (C) Untreated 26S proteasomes were resolved on a 
native gel. Following electrophoresis, the gel was incubated with the peptidase substrate 
in the presence of ubistatin. No inhibition could be observed, whereas epoxomicin 
inhibited peptidase activity under identical conditions (not shown). 
 
Fig. S7. Effect of ubistatins on degradation of ornithine decarboxylase (ODC) by purified 
rat proteasomes. (A) Ubistatins A and B were titrated into a reaction containing 50 nM 
35S-labeled ODC and 50 nM proteasomes and incubated for 30 minutes. Data are 
normalized to ODC degradation observed in the absence of competing inhibitors and are 
expressed as residual degradation. (B) Inhibition of  35S-labeled ODC turnover by cold 
ODC or ODC-GA30, a variant that can bind to the proteasome but not be degraded (S18).  
 
Fig. S8. Ubistatin A blocks protein turnover in animal cells. We previously demonstrated 
that Protacs, comprised of a ubiquitin ligase-binding peptide from IκBα linked to a 
target-binding molecule, induce degradation of the target in a proteasome-dependent 
manner by recruiting the target to the SCF ubiquitin ligase (S13, S19). (A) Protac, which 
contains dihydroxytestosterone as the target-binding molecule, induces rapid degradation 
of androgen receptor-GFP (AR-GFP) upon introduction into cells. HEK293 cells 
expressing AR-GFP were injected with Protac alone or Protac plus ubistatin A or 
epoxomicin, and monitored for presence or absence of GFP by fluorescence microscopy. 
Protac induced rapid loss of AR-GFP without compromising cell integrity (as monitored 
by retention of rhodamine dye), but this effect was blocked by simultaneous introduction 
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of either 100 nM ubistatin A (B) or 100 nM epoxomicin (C). (D) Quantitation of results 
from one experiment in which the following number of cells were injected: Protac alone 
(n= 37); Protac + ubistatin A (n=28); Protac + epoxomicin (n=26). The results are 
representative of 3 experiments performed on 3 separate days. 
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Table S1 
Cmpd Class ID # CAS 
C77 IA NSC383123 NA 
C58 IA NSC298884 65562-56-3 
C82 IA NSC519257 66678-51-1 
C62 IA NSC350006 73908-01-7 
C61 IA NSC349960 18822-50-9 
C13 IA C5144324 301860-02-6 
C18 IA NSC7831 1934-20-9 
C25 IA NSC19742 92474-98-1 
C54 IA NSC205359 68341-64-0 
C67 IA NSC350138 81115-64-2 
C40 IA NSC124151 22276-98-8 
C34 IA NSC94017 60-92-4 
C39 IB NSC124149 24386-95-6 
C57 IB NSC279846 73024-72-3 
C51 IB NSC172599 22256-94-6 
C10 IB C5255908 NA 
C1 IIA C5271852 NA 
C2 IIA C5117023 901-47-3 
C8 IIA C145663 NA 
C23 IIB NSC14226 5429-79-8 
C59 IIB NSC306455 NA 
C92 IIB NSC665534 NA 
 
Table S1: Identification numbers for compounds reported in Table 1. “ID#” refers to the 
identification number of the inhibitor obtained from the NCI (prefaced by NSC) or 
Chembridge (prefaced by C). CAS refers to the chemical abstract services number and is 
included where available; NA indicates that a CAS number was not available. 
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